Radiat Oncol J.  2013 Sep;31(3):171-174. 10.3857/roj.2013.31.3.171.

Sorafenib-triggered radiation recall dermatitis with a disseminated exanthematous reaction

• Oh D
• Park HC
• Lim HY
• Yoo BC

• KMID: 2051134
• DOI: http://doi.org/10.3857/roj.2013.31.3.171

Abstract

Sorafenib is a multi-targeted kinase inhibitor, which is the current standard treatment for advanced hepatocellular carcinoma (HCC). Only one case of radiation recall dermatitis (RRD) associated with sorafenib has been reported so far. Our patient with recurrent HCC was treated with palliative radiotherapy (RT) for the chest wall mass. Sorafenib at 400 mg twice daily was begun on the day following RT. On the 14th day post-RT, an erythematous patch was observed on right chest wall which matched area previously irradiated. It was consistent with RRD. Ten days later, a disseminated exanthematous rash and severe pruritus occurred. Sorafenib was stopped and an oral antihistamine was prescribed to relieve symptoms. At the 1-week follow-up after the cessation of sorafenib, all symptoms were resolved. Physicians should be alert to this recall phenomenon as it can occur both in the skin and elsewhere and the occurrence of RRD may be unpredictable.

Keyword

Sorafenib; Radiotherapy; Radiation recall dermatitis

MeSH Terms

Carcinoma, Hepatocellular
Exanthema
Follow-Up Studies
Humans
Niacinamide
Phenylurea Compounds
Phosphotransferases
Pruritus
Radiodermatitis
Skin
Thoracic Wall
Niacinamide
Phenylurea Compounds
Phosphotransferases